J Liver Cancer.  2024 Sep;24(2):126-128. 10.17998/jlc.2024.08.08.

Exploring the role of liver resection as a first-line treatment option for multinodular BCLC-A hepatocellular carcinoma

• Oh JH
• Sinn DH

• KMID: 2559459
• DOI: http://doi.org/10.17998/jlc.2024.08.08

Reference

References

1. Korean Liver Cancer Association (KLCA), National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. J Liver Cancer. 2023; 23:1–120.

2. Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022; 76:681–693.

3. Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023; 78:1922–1965.

4. Oh JH, Sinn DH, Choi GS, Kim JM, Joh JW, Kang TW, et al. Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria. Ann Surg Treat Res. 2020; 99:238–246.

5. Yi HM, Zhang W, Ai X, Li KY, Deng YB. Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma conforming to the Milan criteria: systemic review and meta-analysis. Int J Clin Exp Med. 2014; 7:3150–3163.

6. Romano P, Busti M, Billato I, D’Amico F, Marchegiani G, Pelizzaro F, et al. Liver resection versus radiofrequency ablation or trans-arterial chemoembolization for early-stage (BCLC A) oligo-nodular hepatocellular carcinoma: meta-analysis. BJS Open. 2024; 8:zrad158.

7. Hidaka M, Hara T, Soyama A, Adachi T, Matsushima H, Tanaka T, et al. Long-term outcomes of living-donor liver transplantation, hepatic resection, and local therapy for hepatocellular carcinoma with three <3- cm nodules in a single institute. JGH Open. 2022; 6:539–546.

8. Hsu KF, Chu CH, Chan DC, Yu JC, Shih ML, Hsieh HF, et al. Superselective transarterial chemoembolization vs hepatic resection for resectable early-stage hepatocellular carcinoma in patients with Child-Pugh class a liver function. Eur J Radiol. 2012; 81:466–471.

9. Yang J, Choi WM, Lee D, Shim JH, Kim KM, Lim YS, et al. Outcomes of liver resection and transarterial chemoembolization in patients with multinodular BCLC-A hepatocellular carcinoma. J Liver Cancer. 2024; Apr. 3. doi: 10.17998/jlc.2024.03.25 [Epub ahead of print].

10. Barros AZA, Fonseca GM, Kruger JAP, Coelho FF, Herman P. Liver resection for hepatocellular carcinoma beyond the BCLC: are multinodular disease, portal hypertension, and portal system invasion real contraindications? J Gastrointest Oncol. 2022; 13:3123–3134.

11. Martin D, Smet H, Da Silva Costa AC, Halkic N, Uldry E, Tabrizian P, et al. Tumor burden in patients with early and intermediate-stage hepatocellular carcinoma undergoing liver resection: a retrospective multicenter study on clinical and oncological outcomes. HPB (Oxford). 2023; 25:836–844.

12. Oh JH, Sinn DH. Multidisciplinary approach for hepatocellular carcinoma patients: current evidence and future perspectives. J Liver Cancer. 2024; 24:47–56.

13. Singal AG, Yarchoan M, Yopp A, Sapisochin G, Pinato DJ, Pillai A. Neoadjuvant and adjuvant systemic therapy in HCC: current status and the future. Hepatol Commun. 2024; 8:e0430.

14. Kim H, Jang M, Park YN. Histopathological variants of hepatocellular carcinomas: an update according to the 5th edition of the WHO classification of digestive system tumors. J Liver Cancer. 2020; 20:17–24.